Curated News
By: NewsRamp Editorial Staff
December 31, 2024
Investors Alert: Kyverna Therapeutics Faces Securities Class Action Lawsuit
Discuss on Reddit
LinkedIn
TelegramTLDR
- Lead plaintiff deadline for securities class action lawsuit against Kyverna Therapeutics, Inc. is February 7, 2025.
- Kyverna investors can seek appointment as lead plaintiff by February 7, 2025, or remain an absent class member.
- Kessler Topaz Meltzer & Check, LLP aims to protect investors from fraud and corporate misconduct, seeking justice and recovery.
- Defendants allegedly made false statements related to clinical trial data at Kyverna's IPO, impacting investors and legal proceedings.
Impact - Why it Matters
This news matters as it highlights potential misconduct by Kyverna Therapeutics, Inc. and the opportunity for affected investors to seek legal recourse. Investors who purchased Kyverna stock during the IPO period should take note of the lead plaintiff deadline and consider their options for potential recovery.
Summary
A securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. by the law firm of Kessler Topaz Meltzer & Check, LLP on behalf of investors who purchased Kyverna common stock during its IPO. The complaint alleges that Kyverna made materially false statements regarding adverse data related to one of its clinical trials at the time of the IPO. Investors who suffered losses have until February 7, 2025, to seek lead plaintiff representation through Kessler Topaz Meltzer & Check, LLP.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Investors Alert: Kyverna Therapeutics Faces Securities Class Action Lawsuit
